Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating an "Overweight" rating, suggesting that the industry is expected to outperform the overall market [2][32]. Core Insights - The pharmaceutical sector experienced a slight decline of 0.2% this week, while the Shanghai Composite Index fell by 0.7% and the Wind All A Index (excluding financials and petrochemicals) decreased by 0.5% [2][3]. - The overall valuation of the pharmaceutical sector stands at 30.3 times earnings, ranking 12th among 31 first-level sub-industries [6][14]. - Key developments include the approval of the world's first invasive brain-computer interface in China and the release of significant clinical trial results for innovative drugs [11][16][20]. Market Performance - The pharmaceutical index ranked 13th among 31 first-level sub-industries this week [3]. - Performance across various sub-sectors includes: - Raw materials (+1.3%) - Chemical preparations (-0.8%) - Traditional Chinese medicine (-0.1%) - Blood products (+0.3%) - Vaccines (+1.3%) - Medical devices (-2.0%) - Medical consumables (+4.1%) [6][10]. Recent Key Events - Jiangsu Province has launched an action plan for the innovation and development of the brain-computer interface industry, aiming for breakthroughs in technology by 2027 [11][12]. - The global first implantable brain-computer interface by Borui Kang Medical has been approved, designed for patients with spinal cord injuries [15]. - Significant clinical trial results were published for innovative drugs, including the CSF-1R inhibitor Beijiemai and the treatment for focal onset epilepsy, Azetukalner [16][17]. Company Developments - Lizhu Pharmaceutical's acquisition of the Vietnamese company IMP has been approved, valued at approximately 1.587 billion yuan [20]. - Kanglong Chemical has entered a production cooperation agreement with Eli Lilly for the oral GLP-1 receptor agonist Orforglipron, with an expected investment of 200 million USD [22]. - New drug development activities remain active, with several companies highlighted for their innovative drug candidates [2][19]. Investment Recommendations - Investors are advised to pay attention to companies involved in raw material pharmaceuticals due to recent price increases, including Xinhui Cheng, Zhejiang Pharmaceutical, and Tianxin Pharmaceutical [2]. - Continuous monitoring of innovative drug-related companies is recommended, including Heng Rui Pharmaceutical, Bai Jie Shen Zhou, and Nuo Cheng Jian Hua [2]. - The brain-computer interface sector is also highlighted for potential investment opportunities, with companies like Aipeng Medical and Xiangyu Medical being of interest [2].

证券代码：300357 证券简称：我武生物 公告编号：2026-005 产品名称：人脐带间充质干细胞II型注射液 注册分类：治疗用生物制品1类 申请事项：境内生产药品注册临床试验 剂型：注射剂 适应症：脓毒症和（或）脓毒性休克 药品注册申请人：浙江我武干细胞科技有限公司 根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决定予以 受理。 浙江我武生物科技股份有限公司 关于获得人脐带间充质干细胞 II 型注射液药物临床试验申 请受理通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 日前，浙江我武生物科技股份有限公司（以下简称"公司"）间接控股子公 司浙江我武干细胞科技有限公司（以下简称"浙江干细胞"）获得国家药品监督 管理局发出的《受理通知书》，由浙江干细胞提交的"人脐带间充质干细胞 II 型注射液"（以下简称"本品"）药物临床试验申请已获得正式受理。现将有关 内容公告如下： 一、基本情况 二、后续流程 根据《药品注册管理办法》的规定，国家药品监督管理局药品审评中心（以 下简称"药品审评中心"）将对已受理的药物临床试验申请进行审评，对药物临 ...

浙江我武生物科技股份有限公司 关于总经理辞职的公告 证券代码：300357 证券简称：我武生物 公告编号：2026-004 为维护公司的正常运营秩序，确保经营管理工作的连续性和稳定性，在新任 总经理选聘就任之前，公司董事会过半数董事同意由公司副总经理 HU MUSHUANG（胡沐霜）女士代行总经理职责。后续公司将按照法定程序进行总 经理的选聘工作。 特此公告。 浙江我武生物科技股份有限公司董事会 2026 年 3 月 2 日 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江我武生物科技股份有限公司（以下简称"公司"）董事会近日收到公司 总经理何建明先生提交的辞职报告。因个人及工作调整原因，何建明先生申请辞 去公司总经理职务（其原定任期至公司第六届董事会届满之日止），辞去上述职 务后其仍在公司继续任职（担任研发中心总监职务）。何建明先生的辞职报告自 送达公司董事会时生效。何建明先生将按照公司相关制度做好工作交接，其辞职 不会影响公司的正常运作。 截至本公告披露日，何建明先生未持有公司股份，不存在应当履行而未履行 的承诺事项。何建明先生在担任公司总经理期间 ...

Core Viewpoint - The company, I-Wu Biotech, has received approval for a clinical trial supplement application for its drug "Dog Hair Dander Prick Liquid" from the National Medical Products Administration [2] Group 1 - The approval was obtained from the National Medical Products Administration's government service portal [2] - The clinical trial supplement application was submitted by the company [2]

格隆汇2月27日丨我武生物(300357.SZ)公布，公司从国家药品监督管理局政务服务门户网站下载获得 《药物临床试验补充申请批准通知书》，由公司提交的"狗毛皮屑点刺液"药物临床试验补充申请获得批 准。适应症：用于皮肤点刺试验，辅助诊断与狗毛皮屑致敏相关的I型变态反应性疾病。 ...

适应症：用于皮肤点刺试验，辅助诊断与狗毛皮屑致敏相关的I型变态反应 性疾病。 证券代码：300357 证券简称：我武生物 公告编号：2026-003 浙江我武生物科技股份有限公司 关于获得狗毛皮屑点刺液药物临床试验补充申请批 准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 日前，浙江我武生物科技股份有限公司（以下简称"公司"）从国家药品监 督管理局政务服务门户网站下载获得《药物临床试验补充申请批准通知书》，由 公司提交的"狗毛皮屑点刺液"（以下简称"本品"）药物临床试验补充申请获 得批准。现将有关内容公告如下： 一、基本情况 药品名称：狗毛皮屑点刺液 注册分类：治疗用生物制品 剂型：皮肤点刺试剂 本品与公司已获准上市销售的"粉尘螨皮肤点刺诊断试剂盒"（国药准字 S20080010）、"屋尘螨皮肤点刺诊断试剂盒"（国药准字S20190022）、"黄花 蒿花粉变应原皮肤点刺液"（国药准字S20230024）、白桦花粉变应原皮肤点刺 液（国药准字S20230023）、葎草花粉变应原皮肤点刺液（国药准字S20230025）、 悬铃木花粉变应原皮肤点刺液 ...

Core Insights - Iwubio's stock price increased by 0.11% on February 25, with a trading volume of 141 million yuan, and a net financing buy of -356,700 yuan for the day [1] - The company reported a revenue of 853 million yuan for the first nine months of 2025, representing a year-on-year growth of 16.86%, and a net profit of 345 million yuan, up 26.67% [2] Financing and Margin Trading - On February 25, Iwubio had a total financing and margin trading balance of 465 million yuan, with financing buy of 13.42 million yuan and a financing repayment of 13.77 million yuan [1] - The current financing balance of 463 million yuan accounts for 3.23% of the circulating market value, which is above the 90th percentile of the past year [1] - The margin trading data shows that 16,300 shares were sold short on February 25, with a total value of 446,000 yuan, and a margin balance of 1.44 million yuan, exceeding the 70th percentile of the past year [1] Shareholder Information - As of September 30, 2025, Iwubio had 32,400 shareholders, a decrease of 6.22% from the previous period, while the average circulating shares per person increased by 6.63% to 14,927 shares [2] - The company has distributed a total of 965 million yuan in dividends since its A-share listing, with 369 million yuan distributed in the last three years [3] - Notable institutional shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 1.45 million shares, and new entrants such as Harvest Mutual Fund and Penghua Medical Technology Fund [3]

Market Overview - The biopharmaceutical sector increased by 1.27% on February 3, with Wanzhe Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] Stock Performance - Wanzhe Co., Ltd. (000534) closed at 30.65, with a rise of 10.01% and a trading volume of 313,500 shares, amounting to a transaction value of 921 million yuan [1] - Other notable performers included ST Weiming (002581) with a 5.01% increase, closing at 7.55, and Nearshore Protein (688137) with a 4.84% increase, closing at 44.20 [1] Capital Flow - The biopharmaceutical sector experienced a net outflow of 255 million yuan from institutional investors and 153 million yuan from retail investors, while retail investors saw a net inflow of 408 million yuan [2] - The capital flow for individual stocks showed that Wanzhe Co., Ltd. had a net outflow of 50.83 million yuan from institutional investors, while retail investors contributed a net inflow of 15.59 million yuan [3] Individual Stock Analysis - Eurolin Biotech (688319) had a net inflow of 21.61 million yuan from institutional investors, while ST Weiming (002581) saw a significant net inflow of 13.51 million yuan [3] - Conversely, major outflows were noted in Wanzhe Co., Ltd. and other stocks, indicating varied investor sentiment across the sector [3]

Group 1 - The company, I-Woo Bio (300357), stated that it will fulfill its information disclosure obligations according to the relevant requirements of the "Performance Forecast and Performance Express" section of the Shenzhen Stock Exchange's Growth Enterprise Market listing rules [1]

Market Overview - The biopharmaceutical sector experienced a decline of 1.3% on January 29, with Hualan Vaccine leading the drop [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] Individual Stock Performance - Weigao Bio (002880) saw a closing price of 30.07, with an increase of 4.59% and a trading volume of 88,100 shares, totaling a transaction value of 266 million yuan [1] - Changchun High-tech (000661) closed at 98.30, up 0.92%, with a trading volume of 64,700 shares and a transaction value of 629 million yuan [1] - Other notable performers include Boya Bio (300294) and Zhifei Biological (300122), both with a closing price increase of 0.92% and 0.73% respectively [1] Declining Stocks - Hualan Bio (301207) reported a significant decline of 9.05%, closing at 22.62, with a trading volume of 300,600 shares and a transaction value of 689 million yuan [2] - Junshi Biosciences (688180) fell by 6.02%, closing at 36.82, with a trading volume of 266,100 shares and a transaction value of 1 billion yuan [2] - Other stocks such as Jinkang (688670) and Bohui Innovation (300318) also experienced declines of 5.81% and 4.95% respectively [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 866 million yuan from institutional investors, while retail investors contributed a net inflow of 682 million yuan [2] - Notable net inflows from retail investors were observed in stocks like Shanghai Laishi (002252) and Weigao Bio (002880) [3] - Conversely, stocks such as Zhixiang Quantai (688443) and Weigao Bio (002880) experienced significant net outflows from institutional and speculative investors [3]